IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2020 Earnings Conference Call March 30, 2021 4:30 PM ET Company Participants Fred Schwarzer - President and Chief Executive Officer Misbah Tahir - Chief Financial Officer Bruce Keyt - Chief Scientific Officer Daniel Chen - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Inc. Michael Schmidt - Guggenheim Securities, LLC Brian Abrahams - RBC Capital Markets Asthika Goonewardene - Truist Securities, Inc. Operator Good day, e ...

Pioneering the Development of Engineered IgM Antibodies ASH 2020 Investor Conference Call December 5, 2020 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") with respect to the Company's future financial condition, results of operations, business strategy, expectations, milestones and plans. All statements other tha ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | | | | | | | | November 2020 | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") wi ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | | | | | | | | September 2020 | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") w ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | | | | | | | | Wedbush PacGrow Healthcare Conference | | | | | | | August 2020 | | | | | | | | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | May 2020 | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") with respect to the C ...

IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2019 Earnings Conference Call March 26, 2020 4:30 PM ET Company Participants Fred Schwarzer - CEO Misbah Tahir - CFO Bruce Keyt - Chief Scientific Officer Dan Chen - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Nicolaus Michael Schmidt - Guggenheim Operator Good day, everyone and welcome to the IGM Biosciences Fourth Quarter and Full Year 2019 Financial Results. Today's call is being recorded. At this time, I'd now like to turn the call ov ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | | | | | | | | March 2020 | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") with ...

| --- | --- | --- | --- | --- | --- | |--------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of | | | | | | | Engineered IgM Antibodies for the Treatment of Cancer | | | | | | | February 2020 | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "C ...